Compounders Research Compare

Trevi Therapeutics, Inc.(TRVI)

Biotechnology · New Haven, CT

$13.18-0.54 (-3.94%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

New Haven, CT

34 employees

www.trevitherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jennifer L. Good

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T22:53:02.611Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:53:02.611Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,871,292,551
Total debt · period ending 2026-06-30: 605,000
Cash · period ending 2026-06-30: 54,302,000
TTM operating EBITDA · period ending 2026-06-30: -59,420,000

FMP input reference: 9ce6fbcd26cd45408ca5c48bb89acec7413e4f513cf2411d103b895814b8ecfc

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

TRVI EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

TRVI Competitors' EV/EBITDA Ratio

Trevi Therapeutics, Inc.

Current

Market Cap

$1.87B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Novavax, Inc.

Market Cap

$1.86B

EV/EBITDA Ratio

N/A

TTM Avg

3.29x

3Y Avg

3.29x

5Y Avg

3.29x

BioLife Solutions, Inc.

Market Cap

$1.89B

EV/EBITDA Ratio

170.26x

TTM Avg

162.32x

3Y Avg

213.45x

5Y Avg

213.45x

Zymeworks Inc.

Market Cap

$1.89B

EV/EBITDA Ratio

N/A

TTM Avg

2.25x

3Y Avg

2.25x

5Y Avg

2.25x

Agios Pharmaceuticals, Inc.

Market Cap

$1.89B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Immunome, Inc.

Market Cap

$1.85B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Palvella Therapeutics, Inc.

Market Cap

$1.84B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Astrana Health, Inc.

Market Cap

$1.83B

EV/EBITDA Ratio

13.48x

TTM Avg

17.09x

3Y Avg

17.06x

5Y Avg

16.05x

Sarepta Therapeutics, Inc.

Market Cap

$1.83B

EV/EBITDA Ratio

N/A

TTM Avg

349.46x

3Y Avg

208.93x

5Y Avg

208.93x

Establishment Labs Holdings Inc.

Market Cap

$1.92B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Trevi Therapeutics, Inc. (TRVI)	$1.87B	N/A	N/A	N/A	N/A
Novavax, Inc. (NVAX)vs ›	$1.86B	N/A	3.29x	3.29x	3.29x
BioLife Solutions, Inc. (BLFS)vs ›	$1.89B	170.26x	162.32x	213.45x	213.45x
Zymeworks Inc. (ZYME)vs ›	$1.89B	N/A	2.25x	2.25x	2.25x
Agios Pharmaceuticals, Inc. (AGIO)vs ›	$1.89B	N/A	N/A	N/A	N/A
Immunome, Inc. (IMNM)vs ›	$1.85B	N/A	N/A	N/A	N/A
Palvella Therapeutics, Inc. (PVLA)vs ›	$1.84B	N/A	N/A	N/A	N/A
Astrana Health, Inc. (ASTH)vs ›	$1.83B	13.48x	17.09x	17.06x	16.05x
Sarepta Therapeutics, Inc. (SRPT)vs ›	$1.83B	N/A	349.46x	208.93x	208.93x
Establishment Labs Holdings Inc. (ESTA)vs ›	$1.92B	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics